Unlimited access to the most powerful analytical tools in finance.

Subscribe for $2
Overview
Profile
Amphastar Pharmaceuticals Stock

Amphastar Pharmaceuticals Stock AMPH

AMPH
US03209R1032
A11664

Price

0
Today +/-
-0
Today %
-0 %

Amphastar Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Amphastar Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Amphastar Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Amphastar Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Amphastar Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Amphastar Pharmaceuticals Stock Price History

DateAmphastar Pharmaceuticals Price
6/17/20250 undefined
6/17/202525.93 undefined
6/16/202525.94 undefined
6/13/202525.97 undefined
6/12/202526.44 undefined
6/11/202526.01 undefined
6/10/202527.21 undefined
6/9/202526.37 undefined
6/6/202525.87 undefined
6/5/202525.75 undefined
6/4/202525.87 undefined
6/3/202526.07 undefined
6/2/202525.39 undefined
5/30/202525.72 undefined
5/29/202525.61 undefined
5/28/202525.27 undefined
5/27/202525.60 undefined
5/23/202524.41 undefined
5/22/202524.21 undefined
5/21/202524.25 undefined
5/20/202524.94 undefined
5/19/202524.65 undefined

Amphastar Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Amphastar Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amphastar Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amphastar Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Amphastar Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Amphastar Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Amphastar Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amphastar Pharmaceuticals’s growth potential.

Amphastar Pharmaceuticals Revenue, EBIT and net profit per share

DateAmphastar Pharmaceuticals RevenueAmphastar Pharmaceuticals EBITAmphastar Pharmaceuticals Net Income
2030e975.12 M undefined179.32 M undefined199.12 M undefined
2029e929.22 M undefined285.6 M undefined193.81 M undefined
2028e874.14 M undefined264.18 M undefined185.32 M undefined
2027e797.92 M undefined262.62 M undefined196.96 M undefined
2026e775.04 M undefined241.81 M undefined186.47 M undefined
2025e736.85 M undefined219.7 M undefined167.44 M undefined
2024731.97 M undefined205.42 M undefined159.52 M undefined
2023644.4 M undefined199.69 M undefined137.55 M undefined
2022499 M undefined107.5 M undefined91.4 M undefined
2021437.8 M undefined69.9 M undefined62.1 M undefined
2020349.8 M undefined11 M undefined1.4 M undefined
2019322.4 M undefined0 undefined48.9 M undefined
2018294.7 M undefined-8.6 M undefined-5.7 M undefined
2017240.2 M undefined-3.9 M undefined3.6 M undefined
2016255.2 M undefined15.4 M undefined9.8 M undefined
2015251.5 M undefined-6.7 M undefined-2.8 M undefined
2014210.5 M undefined-17.6 M undefined-10.7 M undefined
2013229.7 M undefined17.6 M undefined11.9 M undefined
2012204.3 M undefined27.5 M undefined18.1 M undefined
2011118.4 M undefined-33.4 M undefined7.8 M undefined
2010130.7 M undefined-6.2 M undefined-10.7 M undefined
2009148.6 M undefined3.8 M undefined-15.1 M undefined

Amphastar Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
148130118204229210251255240294322349437499644731736775797874929975
--12.16-9.2372.8812.25-8.3019.521.59-5.8822.509.528.3925.2114.1929.0613.510.685.302.849.666.294.95
39.1938.4623.7344.1237.9924.2930.6840.7837.5036.3940.6840.9745.5449.7054.8151.0350.6848.1346.8042.6840.1538.26
5850289087517710490107131143199248353373000000
-15-1071811-10-293-54816291137159167186196185193199
--33.33-170.00157.14-38.89-190.91-80.00-550.00-66.67-266.67-1,060.00-97.926,100.0046.7750.5516.065.0311.385.38-5.614.323.11
43.443.443.443.443.4424547.548.446.449.949.149.852.45352.06000000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Amphastar Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Amphastar Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (B)
20112012201320142015201620172018201920202021202220232024
                           
53.750.253.667.866.172.968.289.285.4105.6136.7175.8256.81221.65
23.648.324.622.933.226.83652.245.46678.888.8114.94136.29
4.31.92.40.20.30600.30.40.10.20.531.75
26.251.469.982.370.779.863.669.3110.596.892.8103.6105.83153.74
38.425.822.424.75.74.7149.713.710.99.71011.4920.65
146.2177.6172.9197.9176184.2187.8220.4255.3279.7318.1378.4489.6534.07
95.6107.4116.6138.3142.2152.9180.5210.4253.5280.7271.5264.6315.64344.63
000000000042.415.2111
00000000000000
42.442.139.938.136.246.340.738.337.536.735.634.2610.08587.61
0.30.30.34.53.744.543.63.93.33.13.223.05
1.52.1910.532.140.437.640.53730.239.159.479.1697.12
0.140.150.170.190.210.240.260.290.330.350.350.361.021.04
0.290.330.340.390.390.430.450.510.590.630.670.741.511.58
                           
00000000000066
164.7171.5177.7220.7247.8283.1313.9344.4367.3410.1422.4455.1486.06505.4
43.961.973.863.160.370.972.667.5116.4117.8180.3271.7409.27568.79
000-1.7-2.5-4.7-2.1-4-4.7-3.7-6.8-8.6-8.48-9.18
00000000000000
0.210.230.250.280.310.350.380.410.480.520.60.720.891.07
10.617.720.410.213.916.216.631.325.124.422.220.525.4430.51
35.828.619.426.531.431.440.956.155.274.570.366.7197.92133.35
63.73.518.33.77.73.31.221.19.14.61.619.66
00000000000000
1.122.122.17.610.95.46.318.27.712.32.230.440.23
53.572.165.462.659.960.767.1106.890112.3103.894.8225.41173.76
131610.136.130.232.440.83239.434.274.872.8589.58601.63
3.237.25.801.51.410.90.70.50.100
7.754.634.54.17.99.429.235.446.945.558.5169.78
23.92421.944.934.73850.142.469.570.3122.2118.4648.08671.41
77.496.187.3107.594.698.7117.2149.2159.5182.6226213.2873.49845.17
0.290.330.340.390.40.450.50.560.640.710.820.931.761.91
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Amphastar Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Amphastar Pharmaceuticals's financial health and stability.

Assets

Amphastar Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Amphastar Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Amphastar Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Amphastar Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
20102011201220132014201520162017201820192020202120222023
-1071811-10-2103-64616391137
1011111314131415161821232538
9-29112-8-7-34-1402-16-12
1013-52-213-50012-519-1-32-24
524161321263131344146293964
101121112222317
0024003405384449
2519-131211038393841579789183
-9-9-24-17-18-14-21-35-46-41-33-27-24-38
-10-10-25-18-39-16-39-36-42-50-36-28-32-649
-1000-21-2-18-14-8-2-1-8-610
00000000000000
-5-523-7-2-2-493-3032-1526
-11-10037410-16210-1-12-24-47
-9-823-93227-725-3-2-37-26454
700-2-3000000-560-25
00000000000000
50-3314-16-420-12183229-11
16.279.13-26.2913.42.38-3.7417.184.11-8.620.223.4170.5365.15145.34
00000000000000

Amphastar Pharmaceuticals stock margins

The Amphastar Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amphastar Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amphastar Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Amphastar Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Amphastar Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Amphastar Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Amphastar Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amphastar Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amphastar Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amphastar Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Amphastar Pharmaceuticals Margin History

Amphastar Pharmaceuticals Gross marginAmphastar Pharmaceuticals Profit marginAmphastar Pharmaceuticals EBIT marginAmphastar Pharmaceuticals Profit margin
2030e51.08 %18.39 %20.42 %
2029e51.08 %30.74 %20.86 %
2028e51.08 %30.22 %21.2 %
2027e51.08 %32.91 %24.68 %
2026e51.08 %31.2 %24.06 %
2025e51.08 %29.82 %22.72 %
202451.08 %28.06 %21.79 %
202354.91 %30.99 %21.34 %
202249.88 %21.54 %18.32 %
202145.61 %15.97 %14.18 %
202040.97 %3.14 %0.4 %
201940.91 %0 %15.17 %
201836.31 %-2.92 %-1.93 %
201737.68 %-1.62 %1.5 %
201640.83 %6.03 %3.84 %
201530.74 %-2.66 %-1.11 %
201424.37 %-8.36 %-5.08 %
201337.88 %7.66 %5.18 %
201244.2 %13.46 %8.86 %
201123.73 %-28.21 %6.59 %
201038.41 %-4.74 %-8.19 %
200939.1 %2.56 %-10.16 %

Amphastar Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Amphastar Pharmaceuticals earnings per share therefore indicates how much revenue Amphastar Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amphastar Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amphastar Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amphastar Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amphastar Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Amphastar Pharmaceuticals Revenue, EBIT and net profit per share

DateAmphastar Pharmaceuticals Sales per ShareAmphastar Pharmaceuticals EBIT per shareAmphastar Pharmaceuticals Earnings per Share
2030e18.73 undefined0 undefined3.83 undefined
2029e17.85 undefined0 undefined3.72 undefined
2028e16.79 undefined0 undefined3.56 undefined
2027e15.33 undefined0 undefined3.78 undefined
2026e14.89 undefined0 undefined3.58 undefined
2025e14.15 undefined0 undefined3.22 undefined
202414.06 undefined3.95 undefined3.06 undefined
202312.16 undefined3.77 undefined2.6 undefined
20229.52 undefined2.05 undefined1.74 undefined
20218.79 undefined1.4 undefined1.25 undefined
20207.12 undefined0.22 undefined0.03 undefined
20196.46 undefined0 undefined0.98 undefined
20186.35 undefined-0.19 undefined-0.12 undefined
20174.96 undefined-0.08 undefined0.07 undefined
20165.37 undefined0.32 undefined0.21 undefined
20155.59 undefined-0.15 undefined-0.06 undefined
20145.01 undefined-0.42 undefined-0.25 undefined
20135.29 undefined0.41 undefined0.27 undefined
20124.71 undefined0.63 undefined0.42 undefined
20112.73 undefined-0.77 undefined0.18 undefined
20103.01 undefined-0.14 undefined-0.25 undefined
20093.42 undefined0.09 undefined-0.35 undefined

Amphastar Pharmaceuticals business model

Amphastar Pharmaceuticals Inc is a leading biopharmaceutical company that focuses on the development, manufacturing, and marketing of generic and innovative drugs. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. History Amphastar Pharmaceuticals has a remarkable history in the generic industry. The company was founded by Dr. Jack Y. Zhang and Dr. Zhaocheng Guo, both of whom had doctorates in pharmacy. They initially worked as scientists at other pharmaceutical companies before deciding to start their own company. The beginning was difficult as they had limited financial resources and faced tough competition in the industry. However, the company grew through acquiring smaller competitors and developing its own products. Business Model Amphastar Pharmaceuticals' business model is based on the development, manufacturing, and marketing of generic drugs that meet medical needs. The company specializes in the treatment of diseases such as diabetes, heart disease, infections, and cancer. Utilizing unused patents and collaborations plays an important role in accessing new markets. Divisions Amphastar Pharmaceuticals is divided into three divisions: Human Pharmaceuticals, Veterinary Pharmaceuticals, and API (Active Pharmaceutical Ingredients). The Human Pharmaceuticals division specializes in developing products for the treatment of diseases such as diabetes, heart disease, infections, and cancer. The Veterinary Pharmaceuticals division focuses on developing veterinary drugs for livestock and pets. The API division is responsible for manufacturing raw materials for the pharmaceutical industry. Products Amphastar Pharmaceuticals offers a wide range of products, including inhalation aids for asthma, antidepressants, antidotes for anesthetics, anesthetics, drugs for cancer therapies, as well as for the treatment of HIV infections and nervous system disorders. In the field of veterinary products, Amphastar produces antibiotics, antifungals, vitamins, and hormones for animals. Conclusion Amphastar Pharmaceuticals Inc is a successful biopharmaceutical company specializing in the development, manufacturing, and marketing of generic and innovative drugs for a wide range of diseases. Since its inception, the company has been focused on growth and has continuously evolved through acquiring smaller competitors and developing its own products. The company offers a wide range of products for use in human and veterinary medicine and places special emphasis on providing high-quality drugs. Amphastar Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Amphastar Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Amphastar Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Amphastar Pharmaceuticals shares outstanding

The number of shares was Amphastar Pharmaceuticals in 2024 — This indicates how many shares 52.058 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amphastar Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amphastar Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amphastar Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amphastar Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20250.7 0.74  (5.65 %)2025 Q1
12/31/20240.96 0.92  (-4.55 %)2024 Q4
9/30/20241.01 0.96  (-4.74 %)2024 Q3
6/30/20240.79 0.94  (19.17 %)2024 Q2
3/31/20240.98 1.04  (6.52 %)2024 Q1
12/31/20230.94 0.88  (-6.79 %)2023 Q4
9/30/20230.71 1.15  (62.29 %)2023 Q3
6/30/20230.57 0.65  (13.74 %)2023 Q2
3/31/20230.48 0.62  (27.86 %)2023 Q1
12/31/20220.41 0.73  (76.2 %)2022 Q4
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Amphastar Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

37/ 100

🌱 Environment

4

👫 Social

45

🏛️ Governance

61

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Amphastar Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
13.11552 % Applied Physics & Chemistry Laboratories, Inc.6,827,67903/31/2025
10.61043 % BlackRock Institutional Trust Company, N.A.5,523,578-66,6163/31/2025
4.65497 % Zhang (Jack Yongfeng)2,423,282110,3343/31/2025
4.63778 % The Vanguard Group, Inc.2,414,337-291,7243/31/2025
4.24938 % TD Asset Management Inc.2,212,142371,8563/31/2025
3.08236 % State Street Global Advisors (US)1,604,6148,5043/31/2025
2.60548 % Dimensional Fund Advisors, L.P.1,356,360157,7703/31/2025
2.42729 % Fuller & Thaler Asset Management Inc.1,263,598130,6723/31/2025
2.42289 % Epoch Investment Partners, Inc.1,261,307160,0343/31/2025
2.33513 % Boston Trust Walden Company1,215,624236,7043/31/2025
1
2
3
4
5
...
10

Amphastar Pharmaceuticals Executives and Management Board

Mr. Jack Zhang

(77)
Amphastar Pharmaceuticals President, Chief Executive Officer, Chief Scientific Officer, Director (since 1996)
Compensation 7.72 M

Dr. Mary Luo

(74)
Amphastar Pharmaceuticals Chairman of the Board, Chief Operating Officer, Chief Scientist (since 1996)
Compensation 3.77 M

Mr. William Peters

(56)
Amphastar Pharmaceuticals Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director (since 2014)
Compensation 2.89 M

Mr. Rong Zhou

(65)
Amphastar Pharmaceuticals Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Compensation 2.03 M

Mr. Jacob Liawatidewi

(50)
Amphastar Pharmaceuticals Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director (since 2014)
Compensation 1.78 M
1
2
3

Amphastar Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer0,86-0,330,800,950,960,83
McKesson Stock
McKesson
SupplierCustomer0,66-0,380,590,930,950,87
Cardinal Health Stock
Cardinal Health
SupplierCustomer0,110,220,800,910,630,29
MannKind Stock
MannKind
SupplierCustomer-0,390,220,49-0,54-0,75-0,09
1

Most common questions regarding Amphastar Pharmaceuticals

What values and corporate philosophy does Amphastar Pharmaceuticals represent?

Amphastar Pharmaceuticals Inc represents values of integrity, innovation, and commitment to patient care. As a leading pharmaceutical company, their corporate philosophy focuses on delivering high-quality and affordable medicines to improve health outcomes worldwide. Amphastar Pharmaceuticals Inc is dedicated to advancing medical knowledge and developing innovative therapies that address unmet medical needs. With their patient-centric approach, they strive to enhance access to life-saving medications, ensuring the well-being of individuals and communities. Their commitment to ethical practices and social responsibility is reflected in their extensive range of high-value generic and proprietary products. Amphastar Pharmaceuticals Inc's dedication to excellence and patient welfare sets them apart in the pharmaceutical industry.

In which countries and regions is Amphastar Pharmaceuticals primarily present?

Amphastar Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Amphastar Pharmaceuticals achieved?

Amphastar Pharmaceuticals Inc has achieved significant milestones throughout its history. Some of these achievements include the successful development and commercialization of various generic and branded pharmaceutical products. The company has also received numerous regulatory approvals, expanded its product portfolio, and established strategic partnerships to enhance its market presence. With a strong focus on research and innovation, Amphastar Pharmaceuticals Inc continues to deliver high-quality and affordable medications to meet the needs of patients worldwide.

What is the history and background of the company Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals Inc, a leading pharmaceutical company, has a rich history and background in the healthcare industry. Established in 1996, Amphastar has grown to become a renowned provider of generic and biosimilar products worldwide. The company specializes in developing, manufacturing, and marketing a wide range of quality and affordable pharmaceuticals, including injectables, inhalation products, and intranasal sprays. Amphastar has achieved significant milestones over the years, including FDA approvals for various products and strategic partnerships with global pharmaceutical companies. Committed to enhancing patient care and achieving business excellence, Amphastar Pharmaceuticals Inc continues to shape the future of the healthcare industry through innovation and dedication.

Who are the main competitors of Amphastar Pharmaceuticals in the market?

The main competitors of Amphastar Pharmaceuticals Inc in the market include Teva Pharmaceutical Industries Ltd, Mylan N.V., and Novartis International AG.

In which industries is Amphastar Pharmaceuticals primarily active?

Amphastar Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Amphastar Pharmaceuticals?

The business model of Amphastar Pharmaceuticals Inc involves researching, developing, manufacturing, and marketing generic and specialty injectable and inhalation products. As a leading pharmaceutical company, Amphastar focuses on leveraging its extensive expertise in the development of complex generic and innovative specialty pharmaceuticals. By offering a diverse range of products to address critical medical needs, Amphastar aims to improve patient outcomes and enhance access to cost-effective medications. Furthermore, the company actively seeks partnerships and collaborations to expand its product portfolio and enhance its market presence. Amphastar Pharmaceuticals Inc remains committed to providing high-quality pharmaceuticals and driving healthcare advancements.

What is the P/E ratio of Amphastar Pharmaceuticals 2025?

The P/E ratio cannot be calculated for Amphastar Pharmaceuticals at the moment.

What is the P/S ratio of Amphastar Pharmaceuticals 2025?

The P/S cannot be calculated for Amphastar Pharmaceuticals currently.

What is the Quality Investing of Amphastar Pharmaceuticals?

The Quality Investing for Amphastar Pharmaceuticals is 6/10.

What is the revenue of Amphastar Pharmaceuticals 2025?

The expected Amphastar Pharmaceuticals revenue is 736.85 M USD.

How high is the profit of Amphastar Pharmaceuticals 2025?

The expected Amphastar Pharmaceuticals profit is 167.44 M USD.

What is the business model of Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Inc. is a publicly traded company based in California, USA, specializing in the development, manufacturing, and marketing of injectable and inhalable pharmaceutical products. It was founded in 1996 and has built a wide range of products used in various therapy areas such as anesthesia, cardiology, emergency medicine, oncology, endocrinology, and neurology. The main business of Amphastar is the manufacturing and sale of injectable generic drugs used in hospitals and healthcare facilities. Some of the notable products include Ampicillin and Cefazolin, antibiotics used for treating infections. The company also produces anesthesia medications such as Lidocaine, Ketamine, and Midazolam, as well as adrenaline used for life-threatening allergic reactions. Another area of business for Amphastar is injectable Heparin products used for preventing blood clots. These products are sold under the brand names Amphastar and Nanjing Pharmaceutical. Amphastar also produces and distributes Naloxone hydrochloride injections used for opioid overdoses, as well as Enoxaparin injections used for preventing blood clots in patients after surgeries. In addition to injectable products, Amphastar has a pipeline of inhalable products in development, which offer promising growth opportunities. These products are specifically intended for treating respiratory diseases such as COPD and asthma. They are sold under the brand names Primatene Mist and Epinephrine. The company also has a division in the contract manufacturing of pharmaceutical active ingredients and raw materials, including analysis and quality control. Amphastar's customers primarily consist of other pharmaceutical companies that are unable or unwilling to manufacture certain products themselves. Amphastar primarily operates in the USA but also exports a significant portion of its products to Europe, Asia, and other parts of the world. The company has distribution partners in many countries and collaborates closely with distributors and wholesalers to distribute its products. Amphastar's business model is based on a combination of manufacturing its own products, contract manufacturing, and expanding its product portfolio through the development of inhalable products. The company emphasizes high quality and strict regulatory standards to gain the trust of its customers and investors. Amphastar has obtained international GMP standards, FDA approval, and numerous other certifications to ensure the quality and safety of its products. In summary, Amphastar Pharmaceuticals Inc. is a leading provider of injectable pharmaceuticals, also involved in the development of inhalable products. The company has fueled its growth through a combination of its own products and contract manufacturing and aims to expand its product portfolio to increase market share in the USA and internationally.

What is the Amphastar Pharmaceuticals dividend?

Amphastar Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Amphastar Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Amphastar Pharmaceuticals or the company does not pay out a dividend.

What is the Amphastar Pharmaceuticals ISIN?

The ISIN of Amphastar Pharmaceuticals is US03209R1032.

What is the Amphastar Pharmaceuticals WKN?

The WKN of Amphastar Pharmaceuticals is A11664.

What is the Amphastar Pharmaceuticals ticker?

The ticker of Amphastar Pharmaceuticals is AMPH.

How much dividend does Amphastar Pharmaceuticals pay?

Over the past 12 months, Amphastar Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amphastar Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Amphastar Pharmaceuticals?

The current dividend yield of Amphastar Pharmaceuticals is .

When does Amphastar Pharmaceuticals pay dividends?

Amphastar Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Amphastar Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amphastar Pharmaceuticals located?

Amphastar Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amphastar Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amphastar Pharmaceuticals from 6/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/17/2025.

When did Amphastar Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/17/2025.

What was the dividend of Amphastar Pharmaceuticals in the year 2024?

In the year 2024, Amphastar Pharmaceuticals distributed 0 USD as dividends.

In which currency does Amphastar Pharmaceuticals pay out the dividend?

The dividends of Amphastar Pharmaceuticals are distributed in USD.

All fundamentals about Amphastar Pharmaceuticals

Our stock analysis for Amphastar Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amphastar Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.